Sugi Predict
/ Targets
/ PLK1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PLK1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma |
PHASE2 | WITHDRAWN |
| Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer |
PHASE2 | RECRUITING |
| Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer |
PHASE2 | COMPLETED |
| Pembrolizumab (MK-3475) in MM Patients With Residual Disease |
PHASE2 | COMPLETED |
| Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer |
PHASE2 | COMPLETED |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
PHASE2 | UNKNOWN |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial |
PHASE2 | SUSPENDED |
| Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets |
PHASE1/PHASE2 | SUSPENDED |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) |
PHASE2 | COMPLETED |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia |
PHASE2 | COMPLETED |
| BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours |
PHASE1 | COMPLETED |
| Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
PHASE1 | COMPLETED |
| Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors |
PHASE1 | COMPLETED |
| Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma |
PHASE1 | COMPLETED |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas |
PHASE1 | COMPLETED |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck |
PHASE1 | COMPLETED |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC |
EARLY_PHASE1 | COMPLETED |
| Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer |
nan | COMPLETED |
| Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies. |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a PLK1 binder may also engage these)